Stock of the Day

August 15, 2024

PAVmed (PAVM)

$5.94
-$0.08 (-1.3%)
Market Cap: $5.90M

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Today's Trend

PAVmed Inc. (PAVM) — The stock moved lower today after an extreme short-term rally. The key driver this week was a major contract win: PAVmed’s subsidiary Lucid Diagnostics secured a U.S. Department of Veterans Affairs (VA) contract for its EsoGuard esophageal DNA test, which triggered heavy buying and multiple trading halts as the name became highly volatile. Profit-taking, volatility controls and the company’s weak near-term fundamentals appear to be driving the pullback.

Bottom line for investors: the VA contract is a real commercial step and was the catalyst for the prior surge, but near-term price moves are being driven by momentum, halts and speculative flows. Monitor contract uptake, any revenue recognition from VA orders, liquidity/volume, and further corporate or regulatory updates before adding exposure.

Recent News